Exact Sciences' Cologuard Now Recommended in ACS Guidelines | GenomeWeb

NEW YORK (GenomeWeb) — Exact Sciences today announced that the American Cancer Society's national guidelines on colorectal cancer prevention and early detection have been updated to reflect the commercial availability of the company's Cologuard cancer screening test.

Cologuard detects cancer-associated mutations and blood biomarkers in stool samples and has been shown to identify 92 percent of colorectal cancers in average risk patients with 87 percent specificity using only a single sample.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.